[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100349616":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":113,"collaborators":115,"id":119,"slug":20,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":120,"sex":126,"minAge":127,"maxAge":20,"enrollmentInfo":128,"targetDuration":20,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Fludatep","EXPERIMENTAL","PET with 18F-Fludarabine",[13],"Drug: 18F-Fludarabine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","18F-Fludarabine","Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Caroline Bodet-Milin, MD","CONTACT","33240084136","caroline.milin@chu-nantes.fr",[28,45,59,72,85,95,100],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"CHU d'Angers","RECRUITING","Angers","49100","France",{"type":35,"coordinates":36},"Point",[37,38],-0.55202,47.47156,{"lat":38,"lon":37},[41,43],{"name":42,"role":24,"phone":20,"phoneExt":20,"email":20},"Pacôme Fosse, MD",{"name":42,"role":44,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":46,"status":30,"city":47,"state":20,"zip":48,"country":33,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"CHU de Brest","Brest","29000",{"type":35,"coordinates":50},[51,52],-4.48628,48.39029,{"lat":52,"lon":51},[55,57],{"name":56,"role":24,"phone":20,"phoneExt":20,"email":20},"Pierre Yves Salaün, MD",{"name":58,"role":44,"phone":20,"phoneExt":20,"email":20},"Pierre Yvese Salaün, MD",{"facility":60,"status":30,"city":61,"state":20,"zip":62,"country":33,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"CHU de Caen","Caen","14000",{"type":35,"coordinates":64},[65,66],-0.35912,49.18585,{"lat":66,"lon":65},[69,71],{"name":70,"role":24,"phone":20,"phoneExt":20,"email":20},"Nicolas Aide, MD",{"name":70,"role":44,"phone":20,"phoneExt":20,"email":20},{"facility":73,"status":30,"city":74,"state":20,"zip":75,"country":33,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"CHU de Nantes","Nantes","44093",{"type":35,"coordinates":77},[78,79],-1.55336,47.21725,{"lat":79,"lon":78},[82,83],{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"name":84,"role":44,"phone":20,"phoneExt":20,"email":20},"Caroline bodet Milin, MD",{"facility":86,"status":87,"city":88,"state":20,"zip":89,"country":33,"cosmosGeoPoint":90,"geoPoint":94,"contacts":20},"Centre Eugène Marquis","WITHDRAWN","Rennes","35000",{"type":35,"coordinates":91},[92,93],-1.67431,48.11109,{"lat":93,"lon":92},{"facility":96,"status":87,"city":88,"state":20,"zip":89,"country":33,"cosmosGeoPoint":97,"geoPoint":99,"contacts":20},"CHU de Rennes",{"type":35,"coordinates":98},[92,93],{"lat":93,"lon":92},{"facility":101,"status":30,"city":102,"state":20,"zip":103,"country":33,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"CHU de Tours","Tours","37000",{"type":35,"coordinates":105},[106,107],0.70398,47.39484,{"lat":107,"lon":106},[110,112],{"name":111,"role":24,"phone":20,"phoneExt":20,"email":20},"Maria Joao Santiago-Ribeiro, MD",{"name":111,"role":44,"phone":20,"phoneExt":20,"email":20},{"type":114,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[116],{"name":117,"class":118},"Cyceron","UNKNOWN","100349616",false,"NCT03832127","Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients","Exploratory Study Evaluating the Interest of PET to 18F-Fludarabine for the Initial Assessment and End-treatment Evaluation of Patients With Symptomatic Multiple Myeloma in the First Line of Treatment, Not Candidates for Marrow Autograft","Myelofludate","Inclusion Criteria:\n\n* Symptomatic MM in the first line in patients who are not candidates for autologous bone marrow transplantation.\n* Patients eligible for one of the treatments considered as standard in a patient who is not eligible for autograft, according to ESMO's European recommendations\n* MM with measurable disease either by the serum evaluation of the monoclonal component or by the determination of free light chains (serum or urinary).\n* Patient affiliated with a social insurance scheme\n* The patient must understand and voluntarily sign the informed consent form\n* Women of childbearing potential must have a serum pregnancy test (performed within 2 days before each PET scan.)\n* Women of childbearing potential must use an effective contraceptive method throughout the course of the study and for 30 days after the last PET.\n* Male patients (vasectomised or not) with a pregnant partner or a partner of childbearing potential must use a condom and a spermicide until 90 days after the last PET.\n* HIV serology known to be negative\n* Karnofsky ≥ 70 or ECOG 0-1\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy or breastfeeding\n* Male or female refusing birth control conditions\n* Primary AL amyloidosis and myeloma complicated by amyloidosis\n* Neutropenia \\\u003C1000 PN \u002F mm3\n* Thrombocytopenia \\\u003C70,000 \u002F mm3\n* Hepatic impairment: bilirubin\\> 35μmol \u002F L and SGOT, SGPT, alkaline phosphatase greater than 3 N\n* Renal impairment defined by creatinine clearance \\\u003C50 ml \u002F min\n* History of other malignancies with the exception of basal cell carcinoma and stage I cervical cancer\n* Severe active infection\n* Active infection with known hepatitis B or C virus.\n* Patient with insulin-dependent or non-insulin-dependent diabetes mellitus.\n* Intolerance or known allergy to any of the study drugs or any of its analogues\n* Psychiatric illness that may interfere with participation in the study\n* Patient under safeguard of justice\n* Intellectual inability to sign informed consent\n* Persons protected by law","ALL","18 Years",{"count":129,"type":130},35,"ESTIMATED","INTERVENTIONAL",[133],"PHASE1","The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.",[136],"Myeloma","2024-06-12",{"date":139,"type":140},"2024-06-14","ACTUAL",{"date":142,"type":140},"2022-09-09",{"date":144,"type":130},"2026-09-09",{"name":5,"class":6},7]